70 new drugs enter the field of vision after the release of the new national medical insurance drug catalogue

[policies and regulations of pharmaceutical network] recently, the catalogue of national basic medical insurance, industrial injury insurance and maternity insurance drugs was released The adjustment of the medical insurance "drug catalogue" is a comprehensive adjustment after the establishment of the State Medical Insurance Bureau It is also a comprehensive sorting out of the catalogue varieties since the release of the 2000 version of the medical insurance catalogue Once released, it quickly attracted attention from all walks of life The catalogue is divided into five parts: general medicine, western medicine, Chinese patent medicine, negotiated medicine during the agreement period and Chinese herbal pieces From the perspective of the varieties of conventional access, the quantity of drugs before and after the adjustment does not change much, but through dynamic adjustment, the drug structure has changed to some extent There are 2643 drugs in the regular access part of this release, including 1322 western drugs and 1321 Chinese patent drugs (including 93 national drugs); Chinese herbal pieces are managed by the access method, including 892 In terms of the varieties transferred out, there are 150 varieties transferred out, about half of which are drugs whose number has been revoked by the State Drug Administration, and the rest are mainly drugs with low clinical value, obvious abuse and better substitution In addition, according to the introduction, 128 drugs to be negotiated have been determined through expert review, all of which are products with high clinical value but relatively expensive price
According to the relevant person in charge, there will be 128 new drugs on the market in the past two years, 10 of which have been approved in the special anti-cancer drug negotiation last year, 18 of which have been added to the newly released regular list of medical insurance drugs in August In addition, 70 new drugs will enter the negotiation, and the remaining 30 new drugs will be excluded for various reasons, such as supply problems, not yet ready to be listed in China, etc 。 Most of the new drugs entered into the negotiation are expensive and have room for price reduction After the negotiation is successful, the selected drugs will be listed in the new version of the national medical insurance category B directory, and the payment standard will remain unchanged for two years According to the new progress, the negotiation time will probably be in November The whole process of new access products is divided into four stages: preparation stage, clinical evaluation stage, evaluation stage and on-site negotiation stage Looking back on the negotiation process of 36 drugs in 2017, it is mainly to clarify the separation of declaration, evaluation and negotiation After careful comparison, it is not difficult to see that the negotiation and access process of 2017 version of the medical insurance catalog is not different from this negotiation Only after the last negotiation, the new access process of the medical insurance catalog tends to be more standardized and rigorous The author believes that the new version of the medical insurance catalogue will directly affect the fate of drug sales in the future For pharmaceutical enterprises, whether the main drugs are listed in the list of Medicare drugs, transferred out of the list of Medicare drugs, or listed in the key regulatory directory will directly affect the income and profits of pharmaceutical enterprises Some experts predict that in the future, the adjustment of the medical insurance catalogue will become normal, especially the dynamic adjustment under the relevant mechanism of innovative drugs and special types of drugs related to clinical urgently needed drugs The era of adjusting the medical insurance catalogue once every seven years will be gone forever For some pharmaceutical companies, the change of medical insurance catalog also means that the business strategy of "relying on sales and marketing to maintain high growth" in the past has been difficult to maintain The government will continue to strengthen the regulation of the pharmaceutical industry, which will be more conducive to speeding up the reshuffle and transformation of pharmaceutical enterprises and changing the production status of "focusing on sales and ignoring research and development".